Henrietta Lacks’s family sues another pharmaceutical company
By Clarence Williams,
The Washington Post
| 08. 10. 2023
The heirs of Henrietta Lacks, the Black woman who died in the 1950s and whose cells have been reproduced for decades in scientific research, filed suit Thursday in Baltimore federal court alleging that a pharmaceutical company profited from using cells without the consent of Lacks or her family.
The action comes almost two weeks after Lacks’s descendants settled litigation with another biotech company that had allegedly profited from the cells despite knowing that they were extracted without her consent. Terms of the litigation were not released.
Thursday’s suit asks a court to force Ultragenyx, a California-based company that focuses on the development and commercialization of products for rare and genetic diseases, to stop the use of Lacks’s cell line without the permission of her family; to create a “trust” for the cells in possession; to reveal the profits earned from use of the cells; and to provide financial relief.
Lacks was a Baltimore mother of five when she was diagnosed with cervical cancer in 1951 at age 31. A Johns Hopkins Hospital doctor took a sample from her tumor without...
Related Articles
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...
By Roni Caryn Rabin, The New York Times | 01.22.2026
The National Institutes of Health said on Thursday it is ending support for all research that makes use of human fetal tissue, eliminating funding for projects both within and outside of the agency.
A ban instituted in June 2019 by...
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...